The identification of driver mutations in the epidermal growth factor receptor (EGFR) as the primary oncogenic event in a subset of lung adenocarcinomas led to a model of targeted treatment and genetic profiling of the disease. EGFR tyrosine kinase inhibitors (TKIs) confer remission in some patients, but use of the EGFR-TKIs is limited to patients with adenocarcinomas who have known activating EGFR mutations. And resistance to TKI treatment has become an increasingly important cause of treatment failure. Therefore, identification of the molecular components involved could lead to the development of effective therapy. Today only a limited number of genetic alterations are studied.

Next Generation Sequencing (NGS) has the potential of becoming an important tool in clinical and therapeutic decision-making in oncology owing to its enhanced sensitivity in DND mutation detection.

Inclusion Criteria:

• patients of bronchial adénocarcinoma with metastases can benefit from first-line therapy - targeted therapy by tyrosine kinase inhibitor(TKI) for EGFR mutation and chemotherapy for non EGFR mutation)
• Patients with epidermoid cancer of the lungs can benefit from chemotherapy
• man and women
• age ≥ 18 years
• Patients have signed a written informed consent form
• Patients are affiliated to s social health insurance

Exclusion Criteria:

• Survival time ≤ 3 months
• Patients with cerebral metastases
• Patients could not benefit from treatment for others diseases
• Pregnancy or breast-feeding
• Incapacity to sign the consent form for psychiatric, behavioural disorders
• Private individuals of freedom or under tutelage